The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Quantitative Myocardial F18-florbetapir Uptake
研究概览
简要总结
The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.
详细描述
F-18 florbetapir is currently used for the early detection of brain amyloid (Alzheimer's disease). The hypothesis is that F-18 florbetapir will detect amyloid deposition in myocardium prior to current non-invasive diagnostic measures, particular electrocardiography with strain and technetium pyrophosphate scintigraphy. The investigators intend to use F-18 florbetapir and assess its correlation between standard non-invasive diagnostic modalities.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with extra-cardiac biopsy-proven AL or ATTR amyloidosis
- •Patients with a ratio of affected to unaffected free light chains >5 or free light chain difference of >50
排除标准
- •Echocardiographic evidence of cardiac amyloidosis with septal and posterior wall thickness ≥ 13mm
- •Contraindication to florbetapir or its components
- •Refusal to participate in the study
研究组 & 干预措施
AL or TTR type amyloidosis
The participants will undergo F-18 florbetapir PET scan.
干预措施: F-18 florbetapir (Drug)
结局指标
主要结局
Quantitative Myocardial F18-florbetapir Uptake
时间窗: at the time of the PET scan
Number of participants with quantitative F18-florbetapir uptake above previously defined control values
次要结局
未报告次要终点